Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
0.00 | -35.00K | -38.00K | 0.00 | 0.00 | EBIT |
58.87M | -43.95M | -37.71M | -19.00M | -11.12M | EBITDA |
58.87M | -30.79M | -35.12M | -10.61M | -1.69M | Net Income Common Stockholders |
45.47M | -30.82M | -37.71M | -29.61M | -12.81M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
285.06M | 269.07M | 288.88M | 128.28M | 8.28M | Total Assets |
294.61M | 277.71M | 298.68M | 129.16M | 8.43M | Total Debt |
3.21M | 3.95M | 4.34M | 0.00 | 0.00 | Net Debt |
-281.86M | -265.12M | -284.54M | -128.28M | -8.28M | Total Liabilities |
9.46M | 8.63M | 9.61M | 175.87M | 26.79M | Stockholders Equity |
285.15M | 269.08M | 289.07M | -46.71M | -18.36M |
Cash Flow | Free Cash Flow | |||
-34.51M | -20.59M | -34.95M | -15.75M | -9.19M | Operating Cash Flow |
-34.50M | -20.43M | -34.92M | -15.75M | -9.19M | Investing Cash Flow |
-10.00K | -169.00K | -36.00K | 0.00 | 0.00 | Financing Cash Flow |
50.51M | 799.00K | 195.99M | 135.75M | 10.82M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | $3.08B | ― | -39.22% | ― | ― | -31.37% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
43 Neutral | $156.51M | ― | -16.41% | ― | ― | -14.76% | |
43 Neutral | $2.90B | ― | -74.17% | ― | ― | -43.10% | |
38 Underperform | $33.26M | ― | -88.91% | ― | ― | 30.37% | |
29 Underperform | $68.74M | ― | -155.76% | ― | 25.77% | 32.56% | |
28 Underperform | $67.69M | ― | -59.64% | ― | ― | -40.59% |
Third Harmonic Bio, Inc. has released a corporate presentation detailing their focus on advancing THB335, a novel treatment for mast cell-mediated inflammatory diseases. The presentation highlights the potential of THB335 to address unmet needs in conditions like chronic spontaneous urticaria, emphasizing its efficacy and convenience over existing treatments. The company is in the early stages of development, with THB335 showing promise in Phase 1 trials, but faces risks typical of early-stage biotech firms, including the need for additional funding and regulatory hurdles.
On February 11, 2025, Third Harmonic Bio, Inc. announced a restructuring plan aimed at reducing operating costs and aligning its workforce with its strategic research and development goals. This plan involves reducing the workforce by approximately 27 employees, or 50%, with severance benefits contingent upon acceptance of a severance agreement, and is expected to incur around $2.3 million in severance and exit costs. After these restructuring costs and other expenses, the company expects to have cash and equivalents of $262 million to $267 million by June 30, 2025.